Lynch portfolio business raises $77m to take total funding to $140m
SOPHiA GENETICS, a health technology company in Mike Lynch’s Invoke portfolio in Cambridge UK, has closed a $77 million investment round to accelerate the democratisation of data- driven medicine.
The round was led by Generation Investment Management, a pioneer of sustainable investing, with offices in London and San Francisco.
Generation was joined by Idinvest Partners, a Paris-based European leader in private equity, alongside existing investors including Balderton Capital and Alychlo.
SOPHiA GENETICS was founded in Switzerland and combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing.
Its technology makes sense of complex genomic and radiomic data through advanced analysis to better diagnose and treat patients, both for oncology and hereditary disorders.
With the new funding round, SOPHiA GENETICS has now raised a total of $140 million. This latest investment will allow the company to further grow the global community of hospitals using its technology. In particular, SOPHiA GENETICS will continue adding talent to reinforce its rapidly expanding presence in the US.
Its universal platform, SOPHiA AI, is deployed by more than 850 hospitals across 77 countries and has already supported the diagnosis of over 300,000 patients.
Dr Jurgi Camblong, CEO and founder of SOPHiA GENETICS, said: “Since we founded the company our goal has been to help make the global healthcare system more sustainable.
“With Generation’s support, we will enable the more rapid adoption of data-driven medicine technology in healthcare for the benefit of patients worldwide.”